Dr Kruse on the Significance of TNBC Day

“It’s always an important time to highlight the challenges that these patients go through, [acknowledge] the journey they’re on, and bring awareness to why we need better treatments in this [setting].”

Megan Kruse, MD, a breast medical oncologist at Cleveland Clinic, highlighted the importance of staying aware of treatment updates and unmet needs for patients with triple-negative breast cancer (TNBC) in honor of National Triple-Negative Breast Cancer Day, which is observed annually on March 3.

Kruse emphasized that the TNBC population often experiences disease outcomes that fall below the benchmarks currently achieved for most patients with breast cancer. According to Kruse, spotlighting this aggressive disease subtype is essential because, although the oncology field has made significant strides in managing breast cancer overall, TNBC management remains a challenge.

Kruse highlighted that the TNBC treatment paradigm has undergone substantial evolution, driven primarily by the integration of immunotherapy and the marked improvements observed through the application of antibody-drug conjugates. Kruse noted that data from several pivotal clinical trials conducted in 2025 have meaningfully advanced standards of care, particularly for patients with metastatic TNBC. This patient subgroup represents the most difficult-to-treat population within the field of breast oncology, she explained, making these recent clinical successes important for moving the needle forward regarding patient outcomes.

Furthermore, Kruse argued that the future of TNBC treatment development requires a more granular understanding of the disease’s molecular architecture. Rather than treating TNBC as a monolithic entity, Kruse suggested that the oncology community must continue to push forward to define the diverse subtypes that exist under the general triple-negative umbrella. Since these various cancers are not uniform, Kruse posited that treatment approaches should be distinct and tailored to the specific characteristics of different types of TNBC to maximize efficacy.

The ultimate goal of these efforts, as detailed by Kruse, is to identify unique targets and vulnerabilities within these populations to further improve and refine treatment strategies. By bringing awareness to the unique challenges associated with treating patients with TNBC, Kruse underscored the urgent need for continued innovation to develop more effective therapies.